Treatment of invasive candidiasis with echinocandins

Mycoses

Volumn 52, Issue 6, 2009, Pages 476-486

  Glöckner, Andreas ^a   Steinbach, Angela ^b   Vehreschild, Jörg Janne ^b   Cornely, Oliver A ^b  

^a Neurologisches Rehabilitationszentrum Greifswald   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Candidemia; Echinocandin; Intensive care; Invasive candidiasis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CARBAMAZEPINE; CASPOFUNGIN; CYCLOSPORIN A; DEXAMETHASONE; EFAVIRENZ; FLUCONAZOLE; MICAFUNGIN; NEVIRAPINE; NIFEDIPINE; PHENYTOIN; RAPAMYCIN; RIFAMPICIN; TACROLIMUS;

ACUTE KIDNEY FAILURE; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ASPERGILLOSIS; BACTERIAL ARTHRITIS; BIOFILM; CANDIDA GUILLIERMONDII; CANDIDA PARAPSILOSIS; CANDIDEMIA; CELL WALL; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCARDITIS; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; FUNGAL CELL; FUNGAL STRAIN; HEMOLYTIC ANEMIA; HUMAN; HYPERBILIRUBINEMIA; INVASIVE CANDIDIASIS; LIVER DISEASE; LIVER DYSFUNCTION; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OSTEOMYELITIS; PHLEBITIS; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SHOCK; STEM CELL TRANSPLANTATION; VOMITING;

ANTIFUNGAL AGENTS; CANDIDIASIS; ECHINOCANDINS; HUMANS; INTENSIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

CANDIDA; FUNGI;

EID: 70350641188     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2008.01645.x     Document Type: Review

References (80)

1. Bassetti M, Righi E, Tumbarello M, Di Biagio A, Rosso R, Viscoli C. Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. Expert Rev Anti Infect Ther 2006 4 : 875 885.
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004 39 : 309 317.
3. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003 9 : 37.
4. Morgan J, Meltzer MI, Plikaytis BD et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005 26 : 540 547.
5. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005 41 : 1232 1239.
6. Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007 60 : 613 618.
7. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006 43 : 25 31.
8. Bassetti M, Trecarichi EM, Righi E et al. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis 2007 58 : 325 331.
9. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005 49 : 3640 3645.
10. Meyer E, Schwab F, Gastmeier P, Ruden H, Heininger A. Antifungal use in intensive care units. J Antimicrob Chemother 2007 60 : 619 624.
11. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007 27 : 369 388.
12. Kim R, Khachikian D, Reboli AC. A comparative evaluation of properties and clinical efficacy of the echinocandins. Expert Opin Pharmacother 2007 8 : 1479 1492.
13. Zambias RA, Hammond ML, Heck JV et al. Preparation and structure-activity relationships of simplified analogues of the antifungal agent cilofungin: a total synthesis approach. J Med Chem 1992 35 : 2843 2855.
14. Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol 1994 48 : 471 497.
15. Nishiyama Y, Uchida K, Yamaguchi H. Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide. J Electron Microsc (Tokyo) 2002 51 : 247 255.
16. Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog 2006 2 : e35.
17. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003 20 : 121 136.
18. Morrison VA. Echinocandin antifungals: review and update. Expert Rev Anti Infect Ther 2006 4 : 325 342.
19. Pfaller MA, Messer SA, Boyken L et al. Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. J Clin Microbiol 2004 42 : 3117 3119.
20. Ostrosky-Zeichner L, Rex JH, Pappas PG et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003 47 : 3149 3154.
21. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 2005 43 : 5425 5427.
22. Pfaller MA, Diekema DJ, Messer SA, Hollis RJ, Jones RN. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother 2003 47 : 1068 1071.
23. Cuenca-Estrella M, Rodriguez D, Almirante B et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 2005 55 : 194 199.
24. Messer SA, Diekema DJ, Boyken L, Tendolkar S, Hollis RJ, Pfaller MA. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol 2006 44 : 324 326.
25. Messer SA, Kirby JT, Sader HS, Fritsche TR, Jones RN. Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J Antimicrob Chemother 2004 54 : 1051 1056.
26. Nett J, Andes D. Candida albicans biofilm development, modeling a host-pathogen interaction. Curr Opin Microbiol 2006 9 : 340 345.
27. Tchekmedyian NS, Newman K, Moody MR et al. Special studies of the Hickman catheter of a patient with recurrent bacteremia and candidemia. Am J Med Sci 1986 291 : 419 424.
28. Shin JH, Kee SJ, Shin MG et al. Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol 2002 40 : 1244 1248.
29. Rodriguez D, Park BJ, Almirante B et al. Impact of early central venous catheter removal on outcome in patients with candidaemia. Clin Microbiol Infect 2007 13 : 788 793.
30. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun 2003 71 : 4333 4340.
31. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002 46 : 1773 1780.
32. Ghannoum MA. Are there antifungals that are effective against biofilms?; Oral presentation; symposium 3. The 16th Congress of the International Society for Human and Animal Mycology, Paris, 25-29 June 2006.
33. Choi HW, Shin JH, Jung SI et al. Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals. Antimicrob Agents Chemother 2007 51 : 1520 1523.
34. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 2006 50 : 2058 2063.
35. Cota J, Carden M, Graybill JR, Najvar LK, Burgess DS, Wiederhold NP. In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob Agents Chemother 2006 50 : 3926 3928.
36. Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006 42 : 938 944.
37. Kahn JN, Garcia-Effron G, Hsu MJ, Park S, Marr KA, Perlin DS. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 2007 51 : 1876 1878.
38. Cheung C, Guo Y, Gialanella P, Feldmesser M. Development of candidemia on caspofungin therapy: a case report. Infection 2006 34 : 345 348.
39. Osherov N, May GS, Albert ND, Kontoyiannis DP. Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae. Antimicrob Agents Chemother 2002 46 : 2462 2469.
40. Wierman M, Obeid K, Baxa D et al. Emergence of Candida glabrata isolates with reduced susceptibility to caspofungin and micafungin, but not anidulafungin. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20 2007 : Abstract M-512.
41. Ali A, Vasquez G, Vager D, Vazquez JA. Pharmacodynamics of echinocandins against Candida spp, including strains with reduced susceptibility to micafungin and caspofungin while retaining anidulafungin activity. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20 2007 : Abstract M-538.
42. Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 2004 48 : 3407 3411.
43. Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin- specific and Candida species-related differences. Antimicrob Agents Chemother 2007 51 : 2257 2259.
44. Melo AS, Colombo AL, Arthington-Skaggs BA. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob Agents Chemother 2007 51 : 3081 3088.
45. Stevens DA, Ichinomiya M, Koshi Y, Horiuchi H. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother 2006 50 : 3160 3161.
46. Clemons KV, Espiritu M, Parmar R, Stevens DA. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother 2006 50 : 1293 1297.
47. Pfizer. Ecalta® Fachinformation. Karlsruhe : Pfizer, 2007.
48. MSD. Cancidas® Fachinformation. Haar : MSD, 2006.
49. Nguyen TH, Hoppe-Tichy T, Geiss HK et al. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother 2007 60 : 100 106.
50. Mistry GC, Migoya E, Deutsch PJ et al. Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations. J Clin Pharmacol 2007 47 : 951 961.
51. Mochizuki N, Matsumoto K, Ohno K et al. Effects of hepatic CYP3A4 activity on disposition of micafungin in liver transplant recipients with markedly small-for-size grafts. Transplant Proc 2006 38 : 3649 3650.
52. Dowell JA, Stogniew M, Krause D, Damle B. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol 2007 47 : 461 470.
53. Garey KW, Pai MP, Suda KJ et al. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf 2007 16 : 919 927.
54. Stone JA, Holland SD, Wickersham PJ et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002 46 : 739 745.
55. Stogniew M, Pu F, Henkel T, Dowell J. Anidulafungin biotransformation in humans is by degradation not metabolism. 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, 10-13 May 2003 : 1223.
56. Astellas Pharma. Mycamine® (Micafungin) Prescribing Information. Deerfield, IL : Astellas Pharma, 2008.
57. Hirata K, Aoyama T, Matsumoto Y et al. Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration. Yakugaku Zasshi 2007 1127 : 897 901.
58. Gubbins PO, Amsden JR. Drug-drug interactions of antifungal agents and implications for patient care. Expert Opin Pharmacother 2005 6 : 2231 2243.
59. Taber SS, Mueller BA. Drug-associated renal dysfunction. Crit Care Clin 2006 22 : 357 374.
60. Amphotericin B. Fachinformation. München : Bristol-Myers Squibb, 2007.
61. Dowell JA, Stogniew M, Krause D, Henkel T, Weston IE. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005 45 : 227 233.
62. Colburn DE, Giles FJ, Oladovich D, Smith JA. In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology 2004 9 : 217 221.
63. Hebert MF, Townsend RW, Austin S et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005 45 : 954 960.
64. Joseph JM, Jain R, Danziger LH. Micafungin: a new echinocandin antifungal. Pharmacotherapy 2007 27 : 53 67.
65. Vazquez JA. The safety of anidulafungin. Expert Opin Drug Saf 2006 5 : 751 758.
66. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002 347 : 2020 2029.
67. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007 369 : 1519 1527.
68. Pappas PG, Rotstein CMF, Betts RF et al. Micafungin versus caspofungin for the treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007 45 : 883 893.
69. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007 356 : 2472 2482.
70. Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994 331 : 1325 1330.
71. Gilead Sciences. Ambisome® (Liposomales Amphotericin B) Fachinformation. Martinsried-München : Gilead Sciences, 2006.
72. Cornely OA, Lasso M, Betts R et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrobiol Chemother 2007 60 : 363 369.
73. Walsh TJ. Echinocandins - an advance in the primary treatment of invasive candidiasis. N Engl J Med 2002 347 : 2070 2072.
74. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007 20 : 133 163.
75. Zepelin MB, Kunz L, Rüchel R, Reichard U, Weig M, Gross U. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. J Antimicrob Chemother 2007 60 : 424 428.
76. Sobel JD, Revankar SG. Echinocandins - first-choice or first-line therapy for invasive candidiasis? N Engl J Med 2007 356 : 2425 2426.
77. Pappas PG. Treatment guidelines for candidiasis. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20 2007 : Presentation 159-14.
78. Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004 38 : 161 189.
79. Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005 366 : 1435 1442.
80. A Phase III, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Isavuconazole Versus Caspofungin Followed by Voriconazole in the Treatment of Candidemia and Other Invasive Candida Infections. Available at: http://www.clinicaltrials.gov, identifier NCT00413218 [accessed on 7 October 2008].